Patents Assigned to Central Sydney Area Health Service
-
Patent number: 7931907Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 6, 2008Date of Patent: April 26, 2011Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Publication number: 20090155771Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 6, 2008Publication date: June 18, 2009Applicants: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid BARTHOLOMEUSZ, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Patent number: 7431933Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: June 8, 2001Date of Patent: October 7, 2008Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Patent number: 7125961Abstract: The acid-labile sub-unit (ALS) of insulin like growth factor binding protein complex in biologically pure form is described. ALS has a molecular weight between 80–115 kd as determined by SDS polyacrylamide gel electrophoresis, run under reducing conditions; and a partial N-terminal amino acid sequence as follows: Gly ??AspProGlyThrProGlyGluAlaGluGlyProAlaCysProAlaAlaCys- Ala wherein the first amino acid may be Gly or Ala. Also described are methods of producing ALS, compositions containing the in-vivo IGF protein complex, methods of detecting ALS in body fluids, recombinant nucleic acid sequences encoding ALS, and expression vectors and host cells containing such nucleic acid sequences.Type: GrantFiled: May 17, 2005Date of Patent: October 24, 2006Assignee: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Publication number: 20030050449Abstract: The acid-labile sub-unit (ALS) of insulin like growth factor binding protein complex in biologically pure form is described.Type: ApplicationFiled: October 9, 2002Publication date: March 13, 2003Applicant: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Patent number: 6465423Abstract: The acid-labile sub-unit (ALS) of insulin like growth factor binding protein complex in biologically pure form is described. ALS has a molecular weight between 80-115 kd as determined by SDS polyacrylamide gel electrophoresis, run under reducing conditions; and a partial N-terminal amino acid sequence as follows: Gly AspProGlyThrProGlyGluAlaGluGlyProAlaCysProAlaAlaCysAla wherein the first amino acid may be Gly or Ala. Also described are methods of producing ALS, compositions containing the in-vivo IGF protein complex, methods of detecting ALS in body fluids, recombinant nucleic acid sequences encoding ALS, and expression vectors and host cells containing such nucleic acid sequences.Type: GrantFiled: March 30, 1999Date of Patent: October 15, 2002Assignee: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Patent number: 5936064Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth. The nucleic acid encoding ALS, antibodies binding thereto, and fragments thereof are also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: August 10, 1999Assignee: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Patent number: 5866360Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth. The nucleic acid encoding ALS, antibodies binding thereto, and fragments thereof are also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: February 2, 1999Assignee: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Patent number: 5817028Abstract: A method as described for testing the susceptibility of a person to asthma. The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.Type: GrantFiled: November 4, 1996Date of Patent: October 6, 1998Assignee: Central Sydney Area Health ServiceInventor: Sandra Doreen Anderson
-
Patent number: 5622836Abstract: The present invention relates to a family of novel antigens associated with malignant cells of bladder carcinomas, and to antibodies, portions or fragments thereof, or single domain antibodies which recognize those antigens. The invention provides methods of detecting bladder carcinomas using those antibodies, fragments or portions thereof, or single domain antibodies, to kits for use in those methods and to methods of treating bladder carcinoma using the antibodies, fragments or portions thereof, or single domain antibodies.Type: GrantFiled: June 14, 1994Date of Patent: April 22, 1997Assignees: The University of Sydney, The Central Sydney Area Health ServiceInventors: Karen Z. Walker, Pamela J. Russell
-
Patent number: 5328891Abstract: DNA isolates coding for insulin-like growth factor binding protein may be used to produce the protein via recombinant expression systems. Insulin-like growth factor binding protein, which generally has a molecular weight of about 53 kD on non-reducing SDS-PAGE, is useful as a binder to insulin-like growth factor and as a metabolic regulator.Type: GrantFiled: January 13, 1993Date of Patent: July 12, 1994Assignees: Genentech, Inc., Central Sydney Area Health ServiceInventors: Robert C. Baxter, William I. Wood
-
Patent number: 5324820Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth.Type: GrantFiled: December 11, 1992Date of Patent: June 28, 1994Assignee: Central Sydney Area Health ServiceInventor: Robert C. Baxter
-
Patent number: 5258287Abstract: DNA isolates coding for insulin-like growth factor binding protein may be used to produce the protein via recombinant expression systems. Insulin-like growth factor binding protein, which generally has a molecular weight of about 53 kD on non-reducing SDS-PAGE, is useful as a binder to insulin-like growth factor and as a metabolic regulator.Type: GrantFiled: March 22, 1988Date of Patent: November 2, 1993Assignees: Genentech, Inc., Central Sydney Area Health ServiceInventors: Robert C. Baxter, William I. Wood